At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 2,011 enrolled
Drug / intervention
Obeldesivir +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-5245 for the Treatment of COVID-19 in Nonhospitalized Participants
In Brief
A Phase 3 clinical trial evaluating Obeldesivir and Obeldesivir Placebo for COVID-19. Completed, enrolled 2,011 participants across 113 sites in 2 countries.
Detailed Summary
The goal of this clinical study is to test if obeldesivir (GS-5245) is safe and effective for the treatment of coronavirus disease 2019 (COVID-19) in participants who have a standard risk of developing severe illness. This study will also measure how much obeldesivir gets into the blood and how long it takes for the body to get rid of it.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCOVID-19
CountriesJapan, United States
Collaborators--
Timeline
Phase 3CompletedFinished
202420252026
First PostedFeb 2023
Enrollment StartFeb 2023
Primary CompletionNov 2023
Study CompletionJan 2024
TodayJul 2026
First PostedFeb 8, 2023
Enrollment StartFeb 8, 2023
Primary CompletionNov 28, 2023
Study CompletionJan 23, 2024
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 3.4 years ago
Interventions
Obeldesivirdrug
Tablet administered orally without regard to food.
Obeldesivir Placebodrug
Tablet administered orally without regard to food.